AR aberrations and resistance to abiraterone or enzalutamide

摘要

Resistance to abiraterone or enzalutamide is a major medical burden the duration of benefit is highly variable and cross-resistance often occurs when these two agents are given sequentially. Blood-based analysis of androgen receptor splice variants and AR copy number gain or mutations could enhance understanding of the mechanisms of resistance and improve management of patients with castration-resistant prostate cancer.